Journey Medical Corporation to Participate in A.G.P.’s Annual Virtual Healthcare Conference

Rhea-AI Summary

Journey Medical (Nasdaq: DERM) announced that Co-Founder, President and CEO Claude Maraoui will participate in a fireside chat at A.G.P.’s Annual Virtual Healthcare Conference on May 20, 2026. The virtual session is scheduled for 5:00 p.m. ET, with registration via the A.G.P. conference link.

News Market Reaction – DERM

+0.33%

+0.33% Session close to close

In the May 20 session, DERM gained 0.33%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Journey Medical’s participation in a virtual healthcare conference, off...

Analysis

This announcement highlights Journey Medical’s participation in a virtual healthcare conference, offering added visibility for its dermatology portfolio. It follows recent disclosures of revenue growth, improved margins and broader Emrosi™ market access. Investors may track how management messaging at such events ties into previously reported metrics like Q1 2026 performance and ongoing regulatory filings, while also noting the company’s capital-raising flexibility under its effective $150,000,000 shelf registration.

Key Figures

Conference date: May 20, 2026 Fireside chat time: 5:00 p.m. ET

2 metrics

Conference date May 20, 2026 A.G.P.’s Annual Virtual Healthcare Conference participation date

Fireside chat time 5:00 p.m. ET Scheduled start time for Journey Medical’s conference fireside chat

Historical Context

5 past events · Latest: May 13 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 13	Q1 2026 earnings	Positive	+22.4%	Reported Q1 2026 revenue growth, improved margins, and positive Adjusted EBITDA.
May 06	Earnings date notice	Neutral	-4.0%	Announced timing of Q1 2026 results release and accompanying conference call.
Apr 21	Access expansion	Positive	-5.2%	Secured third major GPO contract, expanding Emrosi™ commercial lives coverage.
Mar 25	FY 2025 earnings	Positive	-30.0%	Reported full-year 2025 revenue growth, better gross margin, and narrowed net loss.
Mar 18	Earnings date notice	Neutral	-5.1%	Provided date and time for year-end 2025 financial results and webcast.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent fundamentally positive updates, particularly around Emrosi and revenue growth, often saw mixed to negative price reactions, while one strong Q1 2026 earnings release aligned with a sharp gain.

Recent Company History

Over the last few months, Journey Medical reported multiple milestones. On Mar 25, full-year 2025 results highlighted revenue growth and improved margins but coincided with a -30.01% move. A GPO contract expansion for Emrosi™ on Apr 21 was followed by a -5.2% reaction. In contrast, Q1 2026 earnings on May 13 with stronger growth and narrowed losses aligned with a 22.35% rise. Two “earnings date” notices showed modest negative moves. Today’s conference participation fits into this cadence of frequent investor communications.

Key Terms

nasdaq, fda-approved

2 terms

nasdaq financial

"Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”)"

The Nasdaq is a stock exchange where many companies' shares are bought and sold, functioning much like a marketplace for investments. It matters to investors because it provides a platform to buy and sell ownership stakes in companies, helping them track the value of those companies and make informed decisions. As one of the largest and most technology-focused markets, it also reflects trends and developments in the business world.

View in glossary

fda-approved regulatory

"focused on developing, selling and marketing FDA-approved prescription pharmaceutical products"

FDA-approved means a medical product, drug, device or treatment has passed the U.S. Food and Drug Administration’s review for safety and effectiveness for a specific use. Think of it like a formal safety and performance seal that allows the product to be marketed for that purpose in the U.S.; for investors, approval reduces regulatory uncertainty, enables sales and reimbursement pathways, and can materially affect a company’s revenue prospects and valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SCOTTSDALE, Ariz., May 19, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in a fireside chat at A.G.P.’s Annual Virtual Healthcare Conference, taking place on Wednesday, May 20, 2026. The fireside chat is scheduled to begin at 5:00pm ET.

To register for the conference, visit the A.G.P. Registration Link.

About Journey Medical Corporation
Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”) is a commercial-stage pharmaceutical company that primarily focuses on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The Company currently markets eight branded FDA-approved prescription drugs that help treat and heal common skin conditions. The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatology’s most successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). Journey Medical’s common stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). For additional information about Journey Medical, visit www.journeymedicalcorp.com.

Company Contact:
Jaclyn Jaffe
(781) 652-4500
ir@jmcderm.com

Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
tplohoros@6degreespr.com

FAQ

When will Journey Medical (DERM) present at A.G.P.’s Annual Virtual Healthcare Conference in 2026?

Journey Medical will join a fireside chat at A.G.P.’s Annual Virtual Healthcare Conference on May 20, 2026, at 5:00 p.m. ET. According to Journey Medical, the event is virtual and open to registered participants via the A.G.P. conference platform.

Who will represent Journey Medical (DERM) at the May 20, 2026 A.G.P. virtual healthcare conference?

Journey Medical will be represented by Claude Maraoui, its Co-Founder, President and Chief Executive Officer. According to Journey Medical, Maraoui will participate in a scheduled fireside chat session during A.G.P.’s Annual Virtual Healthcare Conference at 5:00 p.m. ET.

How can investors register to watch Journey Medical’s (DERM) fireside chat at A.G.P.’s 2026 virtual conference?

Investors can register through the A.G.P. Registration Link provided for the conference. According to Journey Medical, access to the May 20, 2026, 5:00 p.m. ET fireside chat requires successful online registration via the A.G.P. virtual event portal.

What type of event is Journey Medical (DERM) joining at A.G.P.’s Annual Virtual Healthcare Conference in May 2026?

Journey Medical is joining a fireside chat session at A.G.P.’s Annual Virtual Healthcare Conference. According to Journey Medical, the event is a virtual healthcare investor conference, with the company’s fireside chat scheduled for May 20, 2026, at 5:00 p.m. ET.

Is Journey Medical’s (DERM) appearance at A.G.P.’s 2026 virtual healthcare conference in person or online?

The Journey Medical presentation is part of A.G.P.’s Annual Virtual Healthcare Conference and will be held online. According to Journey Medical, the fireside chat occurs virtually on May 20, 2026, at 5:00 p.m. ET for registered attendees.